Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes

Rhea-AI Filing Summary

Kazia Therapeutics director Steven R. S. Coffey filed an initial ownership report showing his equity interests in the company. He holds options over 1,000 American Depositary Shares (ADSs) at an exercise price of $0.3348 expiring on April 30, 2027, granted on April 30, 2024 with quarterly vesting over three years, and options over 75,000 ADSs at $8.00 expiring on July 3, 2027, which vested fully on July 3, 2025. He also directly owns 16,000 ordinary shares. Additional ADS holdings of 845 and 1,122 are held by Coffey Family Investments Pty Limited and Fortune 501 Pty Limited, respectively, and Coffey disclaims beneficial ownership of those securities except for any pecuniary interest. Each ADS may be exchanged at any time for 500 ordinary shares, and the ADSs themselves have no expiration date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Coffey Steven R. S.

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW AUSTRALIA 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	16,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Share Option (Right to Buy)	(1)	04/30/2027	American Depositary Shares(2)(3)	1,000	$0.3348	D
American Depositary Share Option (Right to Buy)	(4)	07/03/2027	American Depositary Shares(2)(3)	75,000	$8	D
American Depositary Shares	(3)	(3)	Ordinary Shares	845	(3)	I	See footnote(5)
American Depositary Shares	(3)	(3)	Ordinary Shares	1,122	(3)	I	See footnote(6)

Explanation of Responses:

1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 30, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on April 30, 2024.

2. Each ADS option is convertible into ADSs upon exercise.

3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.

4. The ADSs subject to the ADS option vested as to 100% on July 3, 2025. The ADS option was granted on July 3, 2025.

5. The ADSs are held directly by Coffey Family Investments Pty Limited, of which the Reporting Person is a director. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 3 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

6. The ADSs are held directly by Fortune 501 Pty Limited. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 3 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jeffrey Bonacorda, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Steven Coffey report owning in Kazia Therapeutics (KZIA) on this Form 3?

Steven Coffey reports options over 1,000 ADSs at $0.3348, options over 75,000 ADSs at $8.00, and 16,000 ordinary shares. He also reports indirect interests in 845 and 1,122 ADSs held by two separate entities.

How do the Kazia Therapeutics (KZIA) ADS options held by Steven Coffey vest and expire?

One ADS option over 1,000 ADSs was granted on April 30, 2024 and vests in equal quarterly installments over three years, expiring on April 30, 2027. A second ADS option over 75,000 ADSs vested 100% on July 3, 2025 and expires on July 3, 2027.

How are Kazia Therapeutics (KZIA) American Depositary Shares related to ordinary shares?

Each American Depositary Share (ADS) may be represented by 500 ordinary shares of Kazia Therapeutics. Holders can elect to surrender ADSs and withdraw the corresponding number of ordinary shares at any time, and the ADSs themselves have no expiration date.

Which entities hold indirect Kazia Therapeutics (KZIA) ADS positions associated with Steven Coffey?

Indirect ADS holdings are reported for Coffey Family Investments Pty Limited and Fortune 501 Pty Limited. They hold 845 and 1,122 ADSs respectively. Coffey is a director of Coffey Family Investments Pty Limited and disclaims beneficial ownership in both entities except for any pecuniary interest.

Does this Kazia Therapeutics (KZIA) Form 3 show any recent buying or selling by Steven Coffey?

No specific buy or sell transactions are identified; the entries are reported as holdings. The filing summarizes Coffey’s existing options, direct ordinary share ownership, and indirect ADS interests, rather than recording new market purchases or sales.